Published in Int J Radiat Oncol Biol Phys on June 01, 2010
Human epidermal growth factor receptor 3 (HER3) blockade with U3-1287/AMG888 enhances the efficacy of radiation therapy in lung and head and neck carcinoma. Discov Med (2013) 0.88
Co-inhibition of epidermal growth factor receptor and insulin-like growth factor receptor 1 enhances radiosensitivity in human breast cancer cells. BMC Cancer (2013) 0.84
Association of Human Epidermal Growth Factor Receptor 2 with Radiotherapy Resistance in Patients with T1N0M0 Breast Cancer. J Breast Cancer (2013) 0.80
Brain metastasis in human epidermal growth factor receptor 2-positive breast cancer: from biology to treatment. Radiat Oncol J (2016) 0.79
Xenograft assessment of predictive biomarkers for standard head and neck cancer therapies. Cancer Med (2015) 0.79
Phase I study and biomarker analysis of lapatinib and concurrent radiation for locally advanced breast cancer. Oncologist (2012) 0.78
Radiosensitizing effect of lapatinib in human epidermal growth factor receptor 2-positive breast cancer cells. Oncotarget (2016) 0.75
Synergistic antitumor effect between gefitinib and fractionated irradiation in anaplastic oligodendrogliomas cannot be predicted by the Egfr signaling activity. PLoS One (2013) 0.75
Niche-localized tumor cells are protected from HER2-targeted therapy via upregulation of an anti-apoptotic program in vivo. NPJ Breast Cancer (2017) 0.75
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med (2006) 25.67
Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med (2006) 17.08
The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res (2007) 11.56
Basal-like breast cancer: a critical review. J Clin Oncol (2008) 5.64
A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat (2008) 4.84
ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol (2009) 4.40
The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther (2001) 4.37
Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene (2002) 3.87
EGFR associated expression profiles vary with breast tumor subtype. BMC Genomics (2007) 3.35
ErbB receptors: directing key signaling networks throughout life. Annu Rev Pharmacol Toxicol (2004) 3.18
Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res (2009) 3.14
Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients. J Clin Oncol (2005) 2.95
Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol (2005) 2.77
Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. J Natl Cancer Inst (2008) 2.24
Should we be surprised at the paucity of response to EGFR inhibitors? Lancet Oncol (2009) 2.21
Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting. Clin Cancer Res (2004) 2.04
Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study. Lancet Oncol (2009) 1.99
Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens. Ann Oncol (2009) 1.89
Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy. J Clin Oncol (2008) 1.78
Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: prognostic implications of EGFR immunoreactivity. Breast Cancer Res Treat (2008) 1.62
Epidermal growth factor receptor (EGFR) is transcriptionally induced by the Y-box binding protein-1 (YB-1) and can be inhibited with Iressa in basal-like breast cancer, providing a potential target for therapy. Breast Cancer Res (2007) 1.44
Identification of cell-of-origin breast tumor subtypes in inflammatory breast cancer by gene expression profiling. Breast Cancer Res Treat (2005) 1.34
Synergy between angiostatin and endostatin: inhibition of ovarian cancer growth. Cancer Res (2000) 1.34
Clinical and pathologic aspects of basal-like breast cancers. Nat Clin Pract Oncol (2008) 1.28
Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance. Int J Radiat Oncol Biol Phys (2004) 1.21
ERBB receptor tyrosine kinases and cellular radiation responses. Oncogene (2003) 1.17
C225 antiepidermal growth factor receptor antibody enhances the efficacy of docetaxel chemoradiotherapy. Int J Radiat Oncol Biol Phys (2004) 1.10
Mechanism of lapatinib-mediated radiosensitization of breast cancer cells is primarily by inhibition of the Raf>MEK>ERK mitogen-activated protein kinase cascade and radiosensitization of lapatinib-resistant cells restored by direct inhibition of MEK. Radiother Oncol (2009) 1.01
Evaluation of lapatinib and topotecan combination therapy: tissue culture, murine xenograft, and phase I clinical trial data. Clin Cancer Res (2008) 0.97
Mechanisms of disease: Radiosensitization by epidermal growth factor receptor inhibitors. Nat Clin Pract Oncol (2004) 0.96
Radiosensitization of chemotherapy-refractory, locally advanced or locally recurrent breast cancer with trastuzumab: a phase II trial. Int J Radiat Oncol Biol Phys (2009) 0.95
Radiosensitization of human breast cancer cells by a novel ErbB family receptor tyrosine kinase inhibitor. Int J Radiat Oncol Biol Phys (2000) 0.95
Different classes of EGFR inhibitors may have different potential to improve local tumour control after fractionated irradiation: a study on C225 in FaDu hSCC. Radiother Oncol (2004) 0.95
Epidermal growth factor family receptors and inhibitors: radiation response modulators. Semin Radiat Oncol (2003) 0.91
Radiotherapy with concurrent docetaxel for advanced and recurrent breast cancer. Breast Cancer (2003) 0.91
Clinical biomarkers of kinase activity: examples from EGFR inhibition trials. Cancer Metastasis Rev (2008) 0.89
A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer. Cancer Chemother Pharmacol (2009) 0.87
Update in antiepidermal growth factor receptor therapy in the management of metastatic colorectal cancer. J Oncol (2009) 0.82
A phase I dose escalation trial of gemcitabine with radiotherapy for breast cancer in the treatment of unresectable chest wall recurrences. Breast J (2004) 0.81
Radiation therapy and biologics: a ripe opportunity? Nat Clin Pract Oncol (2006) 0.77
Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA (2006) 24.01
The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res (2007) 11.56
EGFR associated expression profiles vary with breast tumor subtype. BMC Genomics (2007) 3.35
Phosphorylation of Neurogenin2 specifies the migration properties and the dendritic morphology of pyramidal neurons in the neocortex. Neuron (2005) 2.70
Translation of polarity cues into asymmetric spindle positioning in Caenorhabditis elegans embryos. Science (2003) 2.46
Return of the GDI: the GoLoco motif in cell division. Annu Rev Biochem (2004) 2.16
The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells. Cancer Res (2006) 1.94
Involvement of Ras activation in human breast cancer cell signaling, invasion, and anoikis. Cancer Res (2004) 1.75
Axillary lymph node count is lower after neoadjuvant chemotherapy. Am J Surg (2006) 1.69
Central nervous system metastases in women after multimodality therapy for high risk breast cancer. Breast Cancer Res Treat (2004) 1.66
Overexpression of focal adhesion kinase in primary colorectal carcinomas and colorectal liver metastases: immunohistochemistry and real-time PCR analyses. Clin Cancer Res (2003) 1.61
High focal adhesion kinase expression in invasive breast carcinomas is associated with an aggressive phenotype. Mod Pathol (2005) 1.57
Histological characteristics of singleton placentas delivered before the 28th week of gestation. Pathology (2008) 1.56
Upregulation of focal adhesion kinase (FAK) expression in ductal carcinoma in situ (DCIS) is an early event in breast tumorigenesis. Breast Cancer Res Treat (2004) 1.49
American Joint Committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome. J Natl Cancer Inst (2005) 1.49
Structure-based protocol for identifying mutations that enhance protein-protein binding affinities. J Mol Biol (2007) 1.48
Association of p16(INK4a) overexpression with improved outcomes in young patients with squamous cell cancers of the oral tongue. Head Neck (2010) 1.46
CD200 is induced by ERK and is a potential therapeutic target in melanoma. J Clin Invest (2007) 1.45
Characterization of chorioamnionitis in 2nd-trimester C-section placentas and correlation with microorganism recovery from subamniotic tissues. Pediatr Dev Pathol (2008) 1.45
Is less more? Lessons in radiation schedules in breast cancer. J Natl Cancer Inst (2002) 1.45
Overexpression of collagenase 1 (MMP-1) is mediated by the ERK pathway in invasive melanoma cells: role of BRAF mutation and fibroblast growth factor signaling. J Biol Chem (2004) 1.39
FAK overexpression and p53 mutations are highly correlated in human breast cancer. Int J Cancer (2009) 1.35
Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032. Radiother Oncol (2011) 1.35
RKIP downregulates B-Raf kinase activity in melanoma cancer cells. Oncogene (2005) 1.35
MERTK receptor tyrosine kinase is a therapeutic target in melanoma. J Clin Invest (2013) 1.34
Molecular characterization of human breast tumor vascular cells. Am J Pathol (2008) 1.32
Inhibition of HER-2/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer. Cancer Res (2005) 1.24
Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance. Int J Radiat Oncol Biol Phys (2004) 1.21
Similar nucleotide excision repair capacity in melanocytes and melanoma cells. Cancer Res (2010) 1.21
Ras-mediated loss of the pro-apoptotic response protein Par-4 is mediated by DNA hypermethylation through Raf-independent and Raf-dependent signaling cascades in epithelial cells. J Biol Chem (2005) 1.18
The estrogen receptor-alpha A908G (K303R) mutation occurs at a low frequency in invasive breast tumors: results from a population-based study. Breast Cancer Res (2005) 1.14
Use of retrovirus expression of interfering RNA to determine the contribution of activated K-Ras and ras effector expression to human tumor cell growth. Methods Enzymol (2006) 1.11
Established and emerging fluorescence-based assays for G-protein function: Ras-superfamily GTPases. Comb Chem High Throughput Screen (2003) 1.11
Defective cell cycle checkpoint functions in melanoma are associated with altered patterns of gene expression. J Invest Dermatol (2007) 1.11
Context-dependent roles of mutant B-Raf signaling in melanoma and colorectal carcinoma cell growth. Mol Cancer Ther (2007) 1.10
Radiosensitization of epidermal growth factor receptor/HER2-positive pancreatic cancer is mediated by inhibition of Akt independent of ras mutational status. Clin Cancer Res (2010) 1.07
D2 dopamine receptor activation of potassium channels is selectively decoupled by Galpha-specific GoLoco motif peptides. J Neurochem (2005) 1.07
The HER4 cytoplasmic domain, but not its C terminus, inhibits mammary cell proliferation. Mol Endocrinol (2007) 1.05
Never-smokers, never-drinkers: unique clinical subgroup of young patients with head and neck squamous cell cancers. Head Neck (2010) 1.01
Methylation-dependent silencing of CST6 in primary human breast tumors and metastatic lesions. Exp Mol Pathol (2007) 1.01
Mechanism of lapatinib-mediated radiosensitization of breast cancer cells is primarily by inhibition of the Raf>MEK>ERK mitogen-activated protein kinase cascade and radiosensitization of lapatinib-resistant cells restored by direct inhibition of MEK. Radiother Oncol (2009) 1.01
G alpha selectivity and inhibitor function of the multiple GoLoco motif protein GPSM2/LGN. Biochim Biophys Acta (2005) 1.00
Epidermal growth factor receptor autocrine signaling in RIE-1 cells transformed by the Ras oncogene enhances radiation resistance. Cancer Res (2003) 1.00
Fluorescence-based assays for RGS box function. Methods Enzymol (2004) 1.00
RGS14 is a mitotic spindle protein essential from the first division of the mammalian zygote. Dev Cell (2004) 0.99
Targeted next generation sequencing identifies clinically actionable mutations in patients with melanoma. Pigment Cell Melanoma Res (2014) 0.98
A prognostic signature of defective p53-dependent G1 checkpoint function in melanoma cell lines. Pigment Cell Melanoma Res (2012) 0.97
Prevalence of human papillomavirus in oropharyngeal squamous cell carcinoma in the United States across time. Chem Res Toxicol (2014) 0.96
Radiosensitization of chemotherapy-refractory, locally advanced or locally recurrent breast cancer with trastuzumab: a phase II trial. Int J Radiat Oncol Biol Phys (2009) 0.95
The EGF receptor family--multiple roles in proliferation, differentiation, and neoplasia with an emphasis on HER4. Trans Am Clin Climatol Assoc (2003) 0.95
Heregulin-dependent delay in mitotic progression requires HER4 and BRCA1. Mol Cell Biol (2006) 0.94
What do surgery residents do on their call nights? Am J Surg (2004) 0.94
Regulator of G-protein signaling 14 (RGS14) is a selective H-Ras effector. PLoS One (2009) 0.93
Feasibility of breast preserving therapy with single fraction in situ radiotherapy delivered intraoperatively. Ann Surg Oncol (2007) 0.91
Size of residual lymph node metastasis after neoadjuvant chemotherapy in locally advanced breast cancer patients is prognostic. Ann Surg Oncol (2006) 0.90
Comparison of three concomitant boost techniques for early-stage breast cancer. Int J Radiat Oncol Biol Phys (2005) 0.89
A novel high-throughput irradiator for in vitro radiation sensitivity bioassays. Phys Med Biol (2014) 0.88
Dysregulation of the epigenome in triple-negative breast cancers: basal-like and claudin-low breast cancers express aberrant DNA hypermethylation. Exp Mol Pathol (2013) 0.86
Effect of breast compression on lesion characteristic visibility with diffraction-enhanced imaging. Acad Radiol (2009) 0.86
High-affinity immobilization of proteins using biotin- and GST-based coupling strategies. Methods Mol Biol (2010) 0.85
Prevalence of Human Papillomavirus in Oropharyngeal Cancer: A Systematic Review. Cancer J (2015) 0.83
Development of DNA damage response signaling biomarkers using automated, quantitative image analysis. J Histochem Cytochem (2013) 0.83
HPV-associated head and neck cancer: molecular and nano-scale markers for prognosis and therapeutic stratification. Sensors (Basel) (2012) 0.82
Cosmetic outcomes for accelerated partial breast irradiation before surgical excision of early-stage breast cancer using single-dose intraoperative radiotherapy. Int J Radiat Oncol Biol Phys (2010) 0.82
Local control following single-dose intraoperative radiotherapy prior to surgical excision of early-stage breast cancer. Ann Surg Oncol (2011) 0.81
In vivo intraoperative radiotherapy: a novel approach to radiotherapy for early stage breast cancer. Ann Surg Oncol (2007) 0.81
Phase I study and biomarker analysis of lapatinib and concurrent radiation for locally advanced breast cancer. Oncologist (2012) 0.78
Overexpression of the receptor tyrosine kinase Tie-1 intracellular domain in breast cancer. Tumour Biol (2003) 0.78
Applicability of randomized trials in radiation oncology to standard clinical practice. Cancer (2013) 0.78
Normal tissue tolerance for high-grade gliomas: is it an issue? Semin Radiat Oncol (2009) 0.77
Mechanisms of chromosomal instability in melanoma. Environ Mol Mutagen (2014) 0.77
Radiation therapy and biologics: a ripe opportunity? Nat Clin Pract Oncol (2006) 0.77
Use of the ThinPrep method in bile duct brushings: analysis of morphologic parameters associated with malignancy and determination of interobserver reliability. Diagn Cytopathol (2008) 0.77
High-resolution axillary ultrasound is a poor prognostic test for determining pathologic lymph node status in patients undergoing neoadjuvant chemotherapy for locally advanced breast cancer. Am J Surg (2004) 0.76
Wetting the whistle: neurotropic factor improves salivary function. J Clin Invest (2014) 0.75
Potential role of the glycolytic oscillator in acute hypoxia in tumors. Phys Med Biol (2015) 0.75
Human papillomavirus and head and neck cancer. Int J Radiat Oncol Biol Phys (2015) 0.75
Staged sentinel lymph node biopsy before mastectomy facilitates surgical planning for breast cancer patients. Am J Surg (2005) 0.75
Mitigating overdiagnosis and overtreatment in breast cancer: what is the role of the pathologist? Arch Pathol Lab Med (2014) 0.75
Endobronchial clear cell adenocarcinoma occurring in a patient 15 years after treatment for DES-associated vaginal clear cell adenocarcinoma. Gynecol Oncol (2004) 0.75